Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia

被引:0
|
作者
Jingyi Wang
Na He
Ruiqing Wang
Tian Tian
Fengjiao Han
Chaoqin Zhong
Chen Zhang
Mingqiang Hua
Chunyan Ji
Daoxin Ma
机构
[1] Qilu Hospital of Shandong University,Department of Hematology
[2] Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Department of Hematology
[3] University of Nebraska Medical Center,Department of Pathology and Microbiology
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
TET2 and EZH2 play important roles in the epigenetic regulation in many cancers. However, their specific roles in acute myeloid leukemia (AML) pathogenesis remain unknown. Here, the expression, methylation or mutation of EZH2 and TET2 was determined and further correlated with the levels of the chromosome instability (CIN) genes MAD2 and CDC20. We down-regulated EZH2 and TET2 in AML cell lines and assessed the effect on CIN using fluorescence in situ hybridization (FISH). Our results showed that TET2, EZH2, MAD2 and CDC20 were aberrantly expressed in AML patients. The expression level of MAD2 or CDC20 was positively correlated with that of TET2 or EZH2. Hypermethylation of the TET2 gene down-regulated its transcription. Down-regulation of EZH2 or TET2 expression inhibited apoptosis, affected MAD2 and CDC20 expression, and promoted CIN in AML cells. Decitabine treatment restored TET2 methylation and EZH2 transcription and ameliorated CIN in AML. Therefore, TET2 and EZH2 play a tumor-inhibiting role in AML that affects CIN via MAD2 and CDC20.
引用
收藏
相关论文
共 50 条
  • [31] RETRACTED: Clinical Significance of EZH2 in Acute Myeloid Leukemia (Retracted Article)
    Jiao, Weiyun
    Liu, Yuanyuan
    Bao, Yangyi
    COMPUTATIONAL INTELLIGENCE AND NEUROSCIENCE, 2022, 2022
  • [32] Higher EZH2 expression is associated with extramedullary infiltration in acute myeloid leukemia
    Zhu, Qiuhua
    Zhang, Lingxiu
    Li, Xiaodong
    Chen, Fang
    Jiang, Ling
    Yu, Guopan
    Wang, Zhixiang
    Yin, Changxin
    Jiang, Xuejie
    Zhong, Qingxiu
    Zhou, Hongsheng
    Ding, Bingjie
    Wang, Chunli
    Meng, Fanyi
    TUMOR BIOLOGY, 2016, 37 (08) : 11409 - 11420
  • [33] EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patients
    Mechaal, Amal
    Menif, Samia
    Abbes, Salem
    Safra, Ines
    ADVANCES IN MEDICAL SCIENCES, 2019, 64 (02): : 395 - 401
  • [34] Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia
    Tanaka, Satomi
    Miyagi, Satoru
    Sashida, Goro
    Chiba, Tetsuhiro
    Yuan, Jin
    Mochizuki-Kashio, Makiko
    Suzuki, Yutaka
    Sugano, Sumio
    Nakaseko, Chiaki
    Yokote, Koutaro
    Koseki, Haruhiko
    Iwama, Atsushi
    BLOOD, 2012, 120 (05) : 1107 - 1117
  • [35] Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia
    Stoelzel, Friedrich
    Fordham, Sarah E.
    Nandana, Devi
    Lin, Wei-Yu
    Blair, Helen
    Elstob, Claire
    Bell, Hayden L.
    Mohr, Brigitte
    Ruhnke, Leo
    Kunadt, Desiree
    Dill, Claudia
    Allsop, Daniel
    Piddock, Rachel
    Soura, Emmanouela-Niki
    Park, Catherine
    Fadly, Mohd
    Rahman, Thahira
    Alharbi, Abrar
    Wobus, Manja
    Altmann, Heidi
    Roellig, Christoph
    Wagenfuehr, Lisa
    Jones, Gail L.
    Menne, Tobias
    Jackson, Graham H.
    Marr, Helen J.
    Fitzgibbon, Jude
    Onel, Kenan
    Meggendorfer, Manja
    Robinson, Amber
    Bziuk, Zuzanna
    Bowes, Emily
    Heidenreich, Olaf
    Haferlach, Torsten
    Villar, Sara
    Ariceta, Benat
    Diaz, Rosa Ayala
    Altschuler, Steven J.
    Wu, Lani F.
    Prosper, Felipe
    Montesinos, Pau
    Martinez-Lopez, Joaquin
    Bornhaeuser, Martin
    Allan, James M.
    JCI INSIGHT, 2023, 8 (02)
  • [36] Loss of TET2 Increases MHC Class I Expression in Acute Myeloid Leukemia
    Gu, Xiaorong
    Bae, Songa
    Zhang, Yahan
    Williams, Nakisha
    Jiang, Dongxu
    Schlanger, Simon
    Visconte, Valeria
    Maciejewski, Jaroslaw
    Jha, Babal K.
    BLOOD, 2024, 144 : 4159 - 4160
  • [37] Reduced TET2 expression in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Scopim-Ribeiro, Renata
    Machado-Neto, Joao
    Campos, Paula de Melo
    Favaro, Patricia
    Duarte, Adriana S. S.
    Visconte, Valeria
    Lorand-Metze, Irene
    Costa, Fernando Ferreira
    Maciejewski, Jaroslaw P.
    Tiu, Ramon V.
    Olalla Saad, Sara T.
    Traina, Fabiola
    BLOOD, 2012, 120 (21)
  • [38] TET2 mutations in acute myeloid leukemia: a comprehensive study in patients of Sindh, Pakistan
    Shaikh, Abdul Rehman Khalil
    Ujjan, Ikram
    Irfan, Muhammad
    Naz, Arshi
    Shamsi, Tahir
    Khan, Muhammad Tariq Masood
    Shakeel, Muhammad
    PEERJ, 2021, 9
  • [39] TET2 mutation in acute myeloid leukemia: biology, clinical significance, and therapeutic insights
    Gao, Qiang
    Shen, Kefeng
    Xiao, Min
    CLINICAL EPIGENETICS, 2024, 16 (01)
  • [40] Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia
    Yamazaki, Jumpei
    Taby, Rodolphe
    Jelinek, Jaroslav
    Raynal, Noel J. M.
    Cesaroni, Matteo
    Pierce, Sherry A.
    Kornblau, Steven M.
    Bueso-Ramos, Carlos E.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Issa, Jean-Pierre J.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (02):